Published in J Thorac Cardiovasc Surg on August 01, 1975
Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J (1980) 1.37
Predictors of post operative bleeding and blood transfusion in cardiac surgery. Ghana Med J (2009) 0.93
Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut (1977) 0.83
Antifibrinolytic therapy in cardiac surgery. Tex Heart Inst J (1995) 0.82
A prospective study of the clinical benefits of prostacyclin in 554 cardiopulmonary bypass procedures. Tex Heart Inst J (1988) 0.75
Lyme carditis: cardiac abnormalities of Lyme disease. Ann Intern Med (1980) 4.12
Bacteriological and Experimental Researches on Gas Gangrene. Proc R Soc Med (1916) 3.05
A computer-derived protocol to aid in the diagnosis of emergency room patients with acute chest pain. N Engl J Med (1982) 2.28
Tracheobronchial tree: expandable metallic stents used in experimental and clinical applications. Work in progress. Radiology (1986) 2.05
Structure determination of feline panleukopenia virus empty particles. Proteins (1993) 1.99
CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol (1995) 1.93
Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation (1992) 1.89
Structure of a viral procapsid with molecular scaffolding. Nature (1997) 1.85
Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med (1983) 1.85
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer (1984) 1.72
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Pathophysiology of endotoxin shock in the primate. Am J Obstet Gynecol (1970) 1.65
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ (1991) 1.65
Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology (2001) 1.61
Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatr Transplant (1999) 1.60
Chloramine Treatment of Sea Water. Am J Public Health Nations Health (1938) 1.59
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol (1998) 1.54
Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood (1984) 1.44
Diffusing capacity limitations of the extent of lung volume reduction surgery in an animal model of emphysema. J Thorac Cardiovasc Surg (1999) 1.39
The structure of human parvovirus B19 at 8 A resolution. Virology (1994) 1.38
Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb (1993) 1.38
Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J (1980) 1.37
Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood (1993) 1.35
Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem (1986) 1.33
Identical mutations in unrelated families with generalized resistance to thyroid hormone occur in cytosine-guanine-rich areas of the thyroid hormone receptor beta gene. Analysis of 15 families. J Clin Invest (1993) 1.33
Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood (1987) 1.29
The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology (2000) 1.27
Structural analysis of the Spiroplasma virus, SpV4: implications for evolutionary variation to obtain host diversity among the Microviridae. Structure (1998) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost (1984) 1.23
Acute appendicitis following abdominal trauma. Arch Surg (1996) 1.22
Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant (1998) 1.21
Structure of the Maize streak virus geminate particle. Virology (2001) 1.20
Necrosis of skin induced by coumarin in a patient deficient in protein S. BMJ (1989) 1.20
Tunable gauge potential for neutral and spinless particles in driven optical lattices. Phys Rev Lett (2012) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
[Incidence of intramural digestive system hematoma in anticoagulation. Epidemiologic study and clinical aspects of 59 cases observed in Switzerland (1970-1975)]. Schweiz Med Wochenschr (1983) 1.19
High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol (1998) 1.18
Biochemical and physical characterization of parvovirus minute virus of mice virus-like particles. Virology (2000) 1.18
Coeliac disease and diabetes mellitus: a study of 24 patients with HLA typing. Q J Med (1982) 1.17
Association between histocompatability antigens (HLA) and nasal carriage of Staphylococcus aureus. J Med Microbiol (1983) 1.16
Structural and kinetic analysis of the chemical rescue of the proton transfer function of carbonic anhydrase II. Biochemistry (2001) 1.14
Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost (1989) 1.12
Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (1995) 1.11
Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer (1998) 1.11
Relationshiop between phosphorylation and activity of pyruvate dehydrogenase in rat liver mitochondria and the absence of such a relationship for pyruvate carboxylase. J Biol Chem (1978) 1.11
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry (2001) 1.10
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer (1986) 1.10
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Complications following total knee replacement. Clin Orthop Relat Res (1977) 1.09
Family and population studies of HLA and coeliac disease in the West of Ireland. Tissue Antigens (1983) 1.08
Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost (1999) 1.08
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Enzyme immunoassay for the diagnosis of cat-scratch disease defined by polymerase chain reaction. Clin Infect Dis (2001) 1.07
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
Anatomic variations in underdeveloped right ventricle related to tricuspid atresia and stenosis. J Thorac Cardiovasc Surg (1976) 1.06
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest (1982) 1.04
Thromboembolic disease in patients undergoing total knee replacement. J Bone Joint Surg Am (1976) 1.03
Identification of aleutian mink disease parvovirus capsid sequences mediating antibody-dependent enhancement of infection, virus neutralization, and immune complex formation. J Virol (2001) 1.03
Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol (1998) 1.01
Measurement of the polarization of W bosons with large transverse momenta in W + jets events at the LHC. Phys Rev Lett (2011) 0.99
Human thyroxine-binding globulin gene: complete sequence and transcriptional regulation. Mol Endocrinol (1993) 0.98
The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemost (1986) 0.98
Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives. J Med Chem (1992) 0.98
Measurement of the inclusive jet cross section in pp collisions at √s = 7 TeV. Phys Rev Lett (2011) 0.98
Search for neutral minimal supersymmetric standard model Higgs bosons decaying to tau pairs in pp collisions at √s=7 TeV. Phys Rev Lett (2011) 0.97
Pharmacokinetic study of gentamicin-loaded cement in total hip replacements. Comparative effects of varying dosage. J Bone Joint Surg Br (1984) 0.97
Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost (1988) 0.97
Preliminary investigation of the phage phi X174 crystal structure. J Mol Biol (1990) 0.96
Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol (1999) 0.96
Preliminary joint neutron and X-ray crystallographic study of human carbonic anhydrase II. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.96
Calcium ion-induced structural changes in bacteriophage phi X174. J Mol Biol (1994) 0.95
Measurement of associated production of vector bosons and top quark-antiquark pairs in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2013) 0.95
Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res (2010) 0.95
Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost (1986) 0.95
Search for dark matter and large extra dimensions in pp collisions yielding a photon and missing transverse energy. Phys Rev Lett (2012) 0.95
Is warfarin sodium contraindicated in the lactating mother? J Pediatr (1983) 0.94
Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene (1995) 0.93
Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia (1993) 0.93
Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots. J Clin Invest (1984) 0.93
Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg (1993) 0.93
Superior mesenteric and portal vein thrombosis following laparoscopic-assisted right hemicolectomy. Report of a case. Dis Colon Rectum (1996) 0.92
Detection of Epstein-Barr virus DNA by polymerase chain reaction in lymph node biopsies from patients with angioimmunoblastic lymphadenopathy. Br J Haematol (1990) 0.92
Tissue transglutaminase enzyme-linked immunosorbent assay as a screening test for celiac disease in pediatric patients. Pediatrics (2001) 0.92
Reversible, hepatic, lysosomal phospholipidosis in rat induced by subchronic daily administration of trospectomycin sulfate. Biochem Pharmacol (1989) 0.92
A cohort study of breast cancer risk in breast reduction patients. Plast Reconstr Surg (1999) 0.91
Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry. J Neurochem (2001) 0.91
First measurement of Bose-Einstein correlations in proton-proton collisions at √s=0.9 and 2.36 TeV at the LHC. Phys Rev Lett (2010) 0.91
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost (1989) 0.91
In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun (2000) 0.90
Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol (2012) 0.90